Dolitsky SN, Cordeiro Mitchell CN, Stadler SS, et al. - Researchers aimed at evaluating the effectiveness of progestin as a standalone treatment for managing vasomotor and mood symptoms linked with menopause. They systematically searched 892 studies using PubMed and Embase databases identifying seven RCTs involving a total of 601 patients. Heterogeneity was observed in terms of formulation and dose of progesterone in the available literature; administration ranged from 5 to 60 mg of transdermal progesterone, 10 to 20 mg oral medroxyprogesterone acetate, and 300 mg of oral micronized progesterone. Some trials described a beneficial effect with the transdermal route at longer duration and with oral treatment at higher doses for VMS for progesterone-only therapy.